Literature DB >> 16941360

The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.

Yves Traoré1, Berthe-Marie Njanpop-Lafourcade, Kokou-Louis-Sewonou Adjogble, Mathilde Lourd, Seydou Yaro, Boubacar Nacro, Aly Drabo, Isabelle Parent du Châtelet, Judith E Mueller, Muhamed-Kheir Taha, Ray Borrow, Pierre Nicolas, Jean-Michel Alonso, Bradford D Gessner.   

Abstract

BACKGROUND: During the period 2001-2002, Burkina Faso reported its first meningitis epidemic due to Neisseria meningitidis (Nm) serogroup W135, prompting concerns that this serogroup would persist as a cause of epidemic disease.
METHODS: During the period 2002-2005, hospital- and population-based surveillances were conducted in 3 districts in Burkina Faso. Etiology was determined by culture, polymerase chain reaction (PCR), and latex agglutination. Reference laboratories determined phenotype and genotype.
RESULTS: Of 2004 subjects who received a lumbar puncture, 265 were identified as having Nm, including 93 who had Nm serogroup A (NmA) and 146 who had Nm serogroup W135 (NmW135). Over the study period, the proportion of cases due to NmW135 decreased by >75%, primarily because of decreased occurrence among young children and in a single district. During peak epidemic months, the annualized incidence of NmW135 decreased from 146 cases to <1 case per 100,000 population. All but 2 NmW135 isolates were phenotype W135:2a:P1.5,2 (sequence type [ST]-11 clonal complex). All NmA isolates were phenotype A:4:P1-9 (ST-2859 of the ST-5 clonal complex). We identified 1 isolate from serogroup Y (ST-11 clonal complex), 1 isolate from serogroup X that was similar to strains previously associated with epidemic disease, and 1 isolate from serogroup W135 of the newly described ST-4375 complex.
CONCLUSIONS: For unknown reasons, serogroup W135 achieved epidemic status, primarily among young children, and then largely disappeared over a short time period. The continued circulation of multiple strains with epidemic potential emphasizes the need for ongoing surveillance and the potential benefit of vaccines that are protective across serogroups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941360     DOI: 10.1086/507339

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

Review 1.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

2.  Epidemiologic pattern of meningococcal meningitis in northern Cameroon in 2007-2010: contribution of PCR-enhanced surveillance.

Authors:  Denis Massenet; Jacques Birguel; François Azowé; Clifford Ebong; Bouba Gake; Jean-Pierre Lombart; Pascal Boisier
Journal:  Pathog Glob Health       Date:  2013-01       Impact factor: 2.894

3.  African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults.

Authors:  Bradford D Gessner; Judith E Mueller; Seydou Yaro
Journal:  BMC Infect Dis       Date:  2010-02-10       Impact factor: 3.090

Review 4.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

5.  Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Authors:  Ryan T Novak; Jean Ludovic Kambou; Fabien Vk Diomandé; Tiga F Tarbangdo; Rasmata Ouédraogo-Traoré; Lassana Sangaré; Clement Lingani; Stacey W Martin; Cynthia Hatcher; Leonard W Mayer; F Marc Laforce; Fenella Avokey; Mamoudou H Djingarey; Nancy E Messonnier; Sylvestre R Tiendrébéogo; Thomas A Clark
Journal:  Lancet Infect Dis       Date:  2012-07-18       Impact factor: 25.071

Review 6.  Neisseria meningitidis: biology, microbiology, and epidemiology.

Authors:  Nadine G Rouphael; David S Stephens
Journal:  Methods Mol Biol       Date:  2012

7.  Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity.

Authors:  Judith E Mueller; Seydou Yaro; Berthe-Marie Njanpop-Lafourcade; Aly Drabo; Régina S Idohou; Sita S Kroman; Oumarou Sanou; Serge Diagbouga; Yves Traoré; Lassana Sangaré; Raymond Borrow; Bradford D Gessner
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

Review 8.  Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.

Authors:  Elisabeth Kugelberg; Bridget Gollan; Christoph M Tang
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

9.  Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003.

Authors:  Judith E Mueller; Lassana Sangaré; Berthe-Marie Njanpop-Lafourcade; Zekiba Tarnagda; Yves Traoré; Seydou Yaro; Raymond Borrow; Bradford D Gessner; Pierre Nicolas
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

10.  Mobile microbiological laboratory support for evaluation of a meningitis epidemic in Northern Benin.

Authors:  Berthe-Marie Njanpop-Lafourcade; Stéphane Hugonnet; Honoré Djogbe; Agbenoko Kodjo; Adèle Kacou N'douba; Muhamed-Kheir Taha; Philippe Stoeckel; Bradford D Gessner
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.